Nivolumab + Ipilimumab + Sunitinib
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Renal Cell Carcinoma
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Trial Timeline
Oct 16, 2014 → Mar 21, 2025
NCT ID
NCT02231749About Nivolumab + Ipilimumab + Sunitinib
Nivolumab + Ipilimumab + Sunitinib is a phase 3 stage product being developed by Ono Pharmaceutical for Advanced Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02231749. Target conditions include Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Renal Cell Carcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02231749 | Phase 3 | Completed |
Competing Products
20 competing products in Advanced Renal Cell Carcinoma